Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 4/20 | 0.42 |
| ▸ | DRD4 | P21917 | 3/20 | 0.42 |
| ▸ | EPHB3 | P54753 | 7/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | CCNK | O75909 | 1/20 | 0.40 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1371036 | 0.74 | DRD3 (0.43) | DRD3DRD4EPHB3DYRK1ADRD2 | |
| SCHEMBL1693785 | 0.74 | AXL (0.42) | AXLEPHB3MAPTGAA | |
| SCHEMBL12456009 | 0.74 | DRD3 (0.42) | DRD3DRD4EPHB3DYRK1ADRD2 | |
| SCHEMBL19114977 | 0.74 | DRD3 (0.42) | DRD3DRD4EPHB3DYRK1ADRD2 | |
| SCHEMBL84746 | 0.74 | NPC1 (0.47) | DRD3DRD4EPHB3DYRK1ARIPK2 | |
| SCHEMBL22995014 | 0.74 | EPHB3 (0.50) | DRD3DRD4EPHB3DYRK1ADRD2 | |
| SCHEMBL30980412 | 0.74 | EPHB3 (0.53) | DRD3DRD4EPHB3DYRK1ADRD2 | |
| SCHEMBL3485186 | 0.74 | DRD3 (0.47) | DRD3DRD4EPHB3DYRK1ADRD2 | |
| SCHEMBL4285576 | 0.74 | CCNK (0.43) | DRD3DRD4EPHB3DYRK1ADRD2 | |
| SCHEMBL33601 | 0.74 | SMPD3 (0.47) | DRD3DRD4EPHB3DYRK1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720067-A1 | BICYCLIC HETEROARYLAMIDES HAVING GPR68 MODULATING ACTIVITY | Recursion Pharmaceuticals, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4665728-A1 | DDR1 AND DDR2 INHIBITORS HAVING A DIHYDROBENZIMIDAZOLONE CORE | Redx Pharma Limited (GB) | 2025-12-24 | — | — | EP | disclosed |
| WO-2025128848-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| CN-119954831-A | Pyrimidopyrazoles, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-119707953-A | Thiadiazolidinone derivative, and preparation method and application thereof | 中国药科大学 | 2025-03-28 | — | — | CN | disclosed |
| US-20250051309-A1 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. | 2025-02-13 | — | — | US | disclosed |
| US-20250051363-A1 | Substituted Pyrazolopyridines | NEURO3 THERAPEUTICS INC (US) | 2025-02-13 | — | — | US | disclosed |
| WO-2025029897-A1 | SUBSTITUTED PYRAZOLOPYRIDINES | NEURO3 THERAPEUTICS, INC. (US) | 2025-02-06 | — | — | WO | disclosed |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | disclosed |
| WO-2024246559-A1 | BICYCLIC HETEROARYLAMIDES HAVING GPR68 MODULATING ACTIVITY | EXSCIENTIA AI LIMITED (GB) | 2024-12-05 | — | — | WO | disclosed |
| US-8131527-B1 | FGFR pharmacophore compounds | ASTEX THERAPEUTICS LTD. (GB) | 2012-03-06 | — | — | US | disclosed |
| WO-2011101161-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-08-25 | — | — | WO | disclosed |
| US-20110195933-A1 | PYRAZOLO[1,5-A]PYRIDINES AS MARK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-08-11 | — | — | US | disclosed |
| US-20110195933-A1 | PYRAZOLO[1,5-A]PYRIDINES AS MARK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-08-11 | — | — | US | disclosed |
| US-20110195933-A1 | PYRAZOLO[1,5-A]PYRIDINES AS MARK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-08-11 | — | — | US | disclosed |
| EP-2035436-B1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2011-05-25 | — | — | EP | disclosed |
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-06-03 | — | — | US | disclosed |
| US-7381725-B2 | Pyridazine derivatives as ligands for GABA receptors | MERCK SHARP & DOHME LTD. (GB) | 2008-06-03 | — | — | US | disclosed |
| US-7381725-B2 | Pyridazine derivatives as ligands for GABA receptors | MERCK SHARP & DOHME LTD. (GB) | 2008-06-03 | — | — | US | disclosed |
| WO-2004014891-A1 | PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195933-A1 | PYRAZOLO[1,5-A]PYRIDINES AS MARK INHIBITORS | MARK3, MARK4, MARK1 | AXL 1886/4885DRD3 3206/4885DRD4 3459/4885 |
| US-20250051363-A1 | Substituted Pyrazolopyridines | QDPR, DPYD, P2RX4 | AXL 3857/4885DRD3 1857/4885DRD4 1232/4885 |
| US-20250051309-A1 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DUSP2, MKNK2, DUSP22 | AXL 4655/4885DRD3 4812/4885DRD4 4847/4885 |
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | AXL 446/4885DRD3 2173/4885DRD4 2865/4885 |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | AXL 3225/4885DRD3 2267/4885DRD4 1639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.